Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
for Advanced Endometrial Carcinoma
228 locations incl. Virginia
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT07198074·Phase 3·Recruiting·Listed Sep 2025